GENB · Generate Biomedicines Inc. Common Stock
View on chartInsiders & Stakes
| Noubar Afeyan Director | ▲ Buy | Open Market | 1,562,500 Shares held | 3/2/2026 | View profile |
| Stephane Bancel Chief Executive Officer | ▼ Sell | Other | 724,160 Shares held | 3/2/2026 | View profile |
| Michael Nally Chief Executive Officer | ▲ Buy | Open Market | 572,707 Shares held | 3/4/2026 | View profile |
| Frances Arnold Director | ▼ Sell | Open Market | 231,472 Shares held | 9/1/2026 | View profile |
| Jane L. Mendillo | ▲ Buy | Open Market | 1,500 Shares held | 3/2/2026 | View profile |
| Jason Silvers President & CFO | ▲ Buy | Open Market | 1,000 Shares held | 3/2/2026 | View profile |
| Beth Grous Chief People Officer | ▲ Buy | Open Market | 300 Shares held | 3/2/2026 | View profile |
Transaction History
| Frances Arnold | ▼ Sell | Open Market | 1,000 | $16K | 9/1/2026 |
| Michael Nally | ▲ Buy | Open Market | 20,000 | $240K | 3/4/2026 |
| Noubar Afeyan | ▼ Sell | Other | 2,777,752 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 987,491 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 2,777,752 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 12,723,940 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 13,702,224 | — | 3/2/2026 |
| Noubar Afeyan | ▲ Buy | Open Market | 1,562,500 | $25.0M | 3/2/2026 |
| Noubar Afeyan | ▲ Buy | Open Market | 1,562,500 | $25.0M | 3/2/2026 |
| Noubar Afeyan | ▲ Buy | Open Market | 1,562,500 | $25.0M | 3/2/2026 |
| Beth Grous | ▲ Buy | Open Market | 300 | $5K | 3/2/2026 |
| Jason Silvers | ▲ Buy | Open Market | 500 | $8K | 3/2/2026 |
| Jason Silvers | ▲ Buy | Open Market | 500 | $8K | 3/2/2026 |
| Jason Silvers | ▲ Buy | Open Market | 1,000 | $16K | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 12,723,940 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 13,702,224 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 987,491 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 2,777,752 | — | 3/2/2026 |
| Noubar Afeyan | ▼ Sell | Other | 2,777,752 | — | 3/2/2026 |
| Noubar Afeyan | ▲ Buy | Open Market | 1,562,500 | $25.0M | 3/2/2026 |
| Noubar Afeyan | ▲ Buy | Open Market | 1,562,500 | $25.0M | 3/2/2026 |
| Noubar Afeyan | ▲ Buy | Open Market | 1,562,500 | $25.0M | 3/2/2026 |
| Michael Nally | ▼ Sell | Other | 658,327 | — | 3/2/2026 |
| Stephane Bancel | ▼ Sell | Other | 724,160 | — | 3/2/2026 |
| Jane L. Mendillo | ▲ Buy | Open Market | 1,500 | $24K | 3/2/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Generate Biomedicines Doses First Patient in GB-5267 CAR T Trial
Generate Biomedicines announced that the first patient has received the investigational GB-5267 therapy in a first‑in‑human trial at Roswell Park. This marks the first dose of the IL‑18 armored CAR‑T cell product and represents a key step toward clinical development. The announcement signals progress in the company’s pipeline and may influence investor perception of its therapeutic potential.
Generate Biomedicines Doses First Patient in GB-5267 CAR T Trial. Generate Biomedicines announced that the first patient has received the investigational GB-5267 therapy in a first‑in‑human trial at Roswell Park. This marks the first dose of the IL‑18 armored CAR‑T cell product and represents a key step toward clinical development. The announcement signals progress in the company’s pipeline and may influence investor perception of its therapeutic potential.